Categories: News

Form 8.3 -Aon plc

                                                FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1) State Street Global Advisors & Affiliates
Company dealt in Aon plc
Class of relevant security to which
the dealings being disclosed relate
(Note 2)
US$0.01 ordinary shares
Date of dealing 06th January 2021

 

   

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

  Long Short
  Number (%) Number (%)
(1) Relevant securities 9,056,145

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.01685 %

 

   
(2) Derivatives (other than options) N/A      
(3) Options and agreements to
purchase/sell
N/A      
Total 9,056,145

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.01685 %

 

   

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
  Number (%) Number (%)
(1) Relevant securities N/A      
(2) Derivatives (other than options) N/A      
(3) Options and agreements to purchase/sell N/A      
Total N/A      

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 12 206.78
Purchase 36 206.78
Purchase 17,145 206.78
Purchase 104,856 206.78
Purchase 2,142 206.78
Purchase 120 206.78
Purchase 182 206.78
Purchase 680 206.78
Purchase 340 206.78
Purchase 7 206.78
Purchase 112 206.78
Sale 300 206.78
Sale 500 206.78
Sale 77 206.78
Sale 1,800 206.78
Sale 8 206.78
Sale 388 206.78

                                                                                                                                                                                    

 (b) Derivatives transactions (other than options transactions)

Product name,
e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)
N/A      

                                                                                                                                                     
(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling,
purchasing
 varying etc.
Number of
securities to which
the option relates
(Note 7)
Exercise
price
Type, e.g.
American,
European etc.
Expiry
date
Option money
paid/received
per unit
(Note 5)
N/A            

(ii) Exercising

Product name,
e.g. call option
Number of securities Exercise price per
unit
(Note 5)
N/A    

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction
(Note 8)
Details Price per unit
(if applicable)
(Note 5)
N/A    

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
N/A

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure 07th January 2021

 

Contact name Lionel Colaco
Telephone number                                                             020 33956098
If a connected EFM, name of offeree/offeror with which connected N/A
If a connected EFM, state nature of connection (Note 10) N/A

Staff

Recent Posts

Optimi Health Announces Appointment of New Director

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX:…

45 minutes ago

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke…

2 hours ago

BC Platforms and GeneVault partner to unlock access to large-scale real-world and genomic data from under-represented populations

Partnership expands BC Platforms' global patient catchment to include an additional 48 million patient lives…

2 hours ago

EPS Corporation Selects ArisGlobal’s LifeSphere® MultiVigilance

Prominent Japan CRO adopts new safety case processing system to further enhance compliance, automation, and…

2 hours ago

DentScribe Joins Henry Schein One API Exchange as an Authorized Integration Vendor

DentScribe now safely and securely integrates with Dentrix to help dental practices build their best…

2 hours ago

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

5 hours ago